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Respiratory syncytial virus–associated acute respiratory infection (RSV-ARI) constitutes a substantial disease burden in older adults 
aged ≥65 years. We aimed to identify all studies worldwide investigating the disease burden of RSV-ARI in this population. We esti-
mated the community incidence, hospitalization rate, and in-hospital case-fatality ratio (hCFR) of RSV-ARI in older adults, stratified 
by industrialized and developing regions, using data from a systematic review of studies published between January 1996 and April 
2018 and 8 unpublished population-based studies. We applied these rate estimates to population estimates for 2015 to calculate the 
global and regional burdens in older adults with RSV-ARI in the community and in hospitals for that year. We estimated the number 
of in-hospital deaths due to RSV-ARI by combining hCFR data with hospital admission estimates from hospital-based studies. In 
2015, there were about 1.5 million episodes (95% confidence interval [CI], .3 million–6.9 million) of RSV-ARI in older adults in 
industrialized countries (data for developing countries were missing), and of these, approximately 14.5% (214 000 episodes; 95% CI, 
100 000–459 000) were admitted to hospitals. The global number of hospital admissions for RSV-ARI in older adults was estimated 
at 336 000 hospitalizations (uncertainty range [UR], 186 000–614 000). We further estimated about 14 000 in-hospital deaths (UR, 
5000–50 000) related to RSV-ARI globally. The hospital admission rate and hCFR were higher for those aged ≥65 years than for those 
aged 50–64 years. The disease burden of RSV-ARI among older adults is substantial, with limited data from developing countries. 
Appropriate prevention and management strategies are needed to reduce this burden.
Keywords. Respiratory syncytial virus; acute respiratory infection; older adults; disease burden.
Acute respiratory infection (ARI), including pneumonia, con-
stitutes a substantial disease burden in older adults ≥65 years. 
The Global Burden of Disease (GBS), Injuries, and Risk Factors 
Study 2015 estimated that lower respiratory infections have 
caused 1.2 million deaths (uncertainty range [UR], 1.0–1.3) and 
13.5 million disability-adjusted life-years (UR, 11.7 million–14.4 
million) in older adults [1]. Respiratory syncytial virus (RSV) is 
one of the important viral pathogens identified in older adults 
with ARI [2] and is increasingly recognized as a cause of ill-
ness in high-risk adults, including those with chronic lung and 
heart disease. A 4-year prospective cohort study indicated that 
RSV infection developed in 3%–7% of healthy older adults and 
in 4%–10% of high-risk adults [2]. Moreover, in that study, the 
hospitalization rate for RSV-ARI increased with age. An active 
surveillance study across multiple centers in the United States 
estimated that the hospital admission rate of RSV-associated 
community-acquired pneumonia in adults aged 50–64 years was 
0.8 cases/10 000 persons per year, with higher rates in adults aged 
65–79 years (2.5 cases/10 000 persons per year) and ≥80 years 
(5.0 cases/10  000 persons per year) [3]. Therefore, we formed 
a study group on RSV infections in adults to supplement a sys-
tematic literature review with unpublished data. We aimed to 
estimate the incidence, hospital admission rate, and in-hospital 
deaths associated with RSV-ARI in older adults in 2015, world-
wide and stratified by industrialized and developing regions.
METHODS
Search Strategy and Selection Criteria
We conducted a systematic review across 9 databases (in-
cluding 3 Chinese databases) following the approach detailed 
in the PRISMA (Preferred Reporting Items for Systematic 
Reviews and Meta-Analyses) guidelines [4]. Tailored search 
strategies were developed and used to search Medline, Embase, 
Global Health, CINAHL, Web of Science, WHOLIS, China 
applyparastyle “fig//caption/p[1]” parastyle “FigCapt”
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National Knowledge Infrastructure (CNKI), Wanfang Data, 
and Chongqing VIP databases (Supplementary Table 1). All 
searches were restricted to articles with publication dates be-
tween January 1996 and April 2018. No publication status cri-
teria or language restrictions were applied. We included studies 
that fulfilled the selection criteria in Supplementary Panel 1.
Five investigators (T. S., A.  D., A.  K. T., I.  C., and E.  M.) 
conducted the search in English-language databases. Any dis-
agreements were resolved after discussion. Two investigators 
(T. S. and X. L.), whose first language is Chinese, did searches 
and data extraction from Chinese-language databases (CNKI, 
Wanfang, and Chongqing VIP). We contacted investigators 
who led studies on RSV-ARI in older adults, and we identified 
unpublished data from 8 studies. The investigator group agreed 
on a common approach for data analysis and interpretation and 
formulated common case definitions. They used these case defi-
nitions to reanalyze data from their already published work, or 
they shared hitherto unpublished data from ongoing studies.
The protocol of this review was published in the PROSPERO 
database (registration CRD42018095111).
Definitions
We used case definitions of pneumonia and (very) severe 
pneumonia adapted from the World Health Organization 
(WHO) Integrated Management of Adolescent and Adult 
Illness guidelines [5]. The details of the definitions are dis-
played in Supplementary Table 2. RSV infection was laboratory 
confirmed. We categorized countries as either industrialized or 
developing on the basis of the United Nations Children’s Fund’s 
classification 2015 [6] and used this regional classification to 
report our results. The adult population estimates for 2015 
were taken from the United Nations Population Division’s da-
tabase [7].
Statistical Analysis
For all included studies, we applied a continuity correction of 
0.0005 if the number of cases or deaths was 0 [8]. This allowed 
calculation of an incidence rate, hospitalization rate, propor-
tion, or hCFR for these instances and enabled their inclusion 
in subsequent meta-analyses. When the study period was 
>12  months but not in multiples of 1  year, we calculated the 
annualized incidence by adjusting for the population at risk. If 
clinical specimens were systematically collected in a proportion 
of eligible cases and data for all eligible cases were available, we 
scaled results for the proportion sampled.
We performed meta-analyses by region for the RSV-ARI in-
cidence, the hospitalization rate for RSV-ARI, proportion of 
RSV positives among ARI cases hospitalised for ARI  and the 
hCFR of RSV-ARI and reported pooled estimates (with 95% 
confidence intervals [CIs]) primarily for older adults but also 
for other age groups of interest (eg, the 50–64-year age group, 
when data were available). Meta-analysis was performed when 
there were at least 3 studies. We used the random effects model 
(DerSimonian-Laird method) because in-study and between-
study data heterogeneity was anticipated and, thus, different ef-
fect sizes were assumed [9]. The incidence and hospitalization 
rate meta-estimates for RSV-ARI were applied to the ≥65-year-
old regional populations to yield estimates for new episodes of 
RSV-ARI and cases admitted to hospitals in 2015. We validated 
hospitalizations for RSV-ARI estimates with an independent 
data set by abstracting the proportion of ARI hospital admis-
sions that involved RSV-positive cases [10]. We then computed 
meta-estimates of the regional proportion and applied these to 
regional estimates of hospital admissions for ARI in older adults 
in 2015 (Shi, unpublished data). We estimated in-hospital RSV-
ARI deaths by applying regional hCFR meta-estimate to the re-
gional number of RSV-ARI hospital admissions. We estimated 
URs for in-hospital death by using Monte Carlo simulation 
(calculating estimates from 10  000 samples from log-normal 
distributions, with 2.5th and 97.5th centiles defining the UR). 
A similar simulation was performed to generate the global esti-
mate (from regional estimates).
Data were analyzed using Stata, version 13.0, and R, version 
3.0.2.
RESULTS
We identified 6593 records, and 36 articles fulfilled our selec-
tion criteria (Supplementary Figure 1) [2, 11–45]. Another 
8 unpublished studies were contributed by the investigator 
group. Overall, 44 studies had relevant data and were included 
(Supplementary Figure 2). We identified 19 studies from indus-
trialized countries, 24 from developing countries, and 1 from 
a mix of industrialized countries and developing countries. 
Nineteen studies were from urban areas, 8 were from rural 
areas, and 17 were from a mixed population. Among them, 9 
reported the community incidence rate in older adults, 16 re-
ported the hospital admission rate, 19 had proportion data, and 
14 reported the hCFR. The full descriptions of the study charac-
teristics and reported outcomes are available in Supplementary 
Tables 3–6. Most studies only reported data for individuals aged 
≥65  years and did not stratify these by narrower age bands. 
Therefore, we decided to report our primary estimates for older 
adults (ie, those ≥65 years); we also reported data for those aged 
≥50 or 50–64 years, when sufficient data were available.
Nine community-based studies with active case ascertain-
ment reported the RSV-ARI incidence (Table 1). The incidence 
rate of RSV-ARI in older adults from industrialized countries 
was estimated to be 6.7 cases/1000 persons per year (95% CI, 
1.4–31.5). We could not reliably estimate any rate for devel-
oping countries, owing to the paucity of data for this region 
(there was only 1 study from India). The estimated number of 
RSV-ARI cases among older adults in industrialized countries 
was 1.5 million (95% CI, 0.3 million–6.9 million). Only 1 study, 
from Wisconsin, provided data stratified by sex and subtype 
[12], which showed that the incidence rate of RSV-ARI in adults 
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aged ≥50 years was 12.7 cases/per 1000 persons per year (95% 
CI, 9.9–16.3) in men and 17.8 cases/1000 persons per year (95% 
CI, 14.7–21.6) in women, while the rate was 8.0 cases/1000 per-
sons per year (95% CI, 6.4–10.0) for RSV-A and 7.4 cases/per 
1000 persons per year (95% CI, 5.0–9.3) for RSV-B.
Sixteen hospital-based studies with passive case ascertain-
ment reported the hospitalization rate for RSV-ARI in older 
adults. We estimated the RSV-ARI hospitalization rate in older 
adults from industrialized countries to be 1.0 cases/per 1000 per-
sons per year (95% CI, .5–2.1), while the rate was 0.3 cases/per 
1000 persons per year (95% CI, .1–.7) in developing countries. 
In studies with data for adults aged 50–64 years, the hospitaliza-
tion rate for RSV-ARI was 0.3 cases/per 1000 persons per year 
(95% CI, .1–1.7) in industrialized countries (3 studies), while 
the rate was 0.2 cases/per 1000 persons per year (95% CI, .1–.3) 
in developing countries (6 studies). The hospitalization rate was 
higher in industrialized countries as compared to developing 
countries, with overlapping 95% CIs in both age groups. The 
overall number of RSV-ARI cases involving hospital admission 
among older adults was 336 000 (UR, 186 000–614 000).
Nineteen hospital-based studies (without a clear population 
denominator) reported the proportion of RSV-positive cases 
among all hospital admissions for ARI. Using this independent 
data set, we estimated that 252 000 hospital admissions for RSV-
ARI (UR, 178 000–360 000) occurred in older adults in 2015. 
Data were insufficient to provide the number of global and re-
gional hospital admissions stratified by sex or RSV subtype.
Ten published and 4 unpublished studies reported the hCFR 
for older adults with RSV-ARI (17 189 cases). In industrialized 
countries, the hCFR meta-estimate was 1.6% (95% CI, .7%–
3.8%), while it was 9.1% (95% CI, 2.6%–31.8%) in developing 
countries. Seven studies also reported the hCFR in those aged 
50–64 years: 1.4% (95% CI, .5–3.6) from industrialized coun-
tries (3 studies) and 2.5% (95% CI, .6%–9.9%) from developing 
countries (4 studies). The hCFR was higher in older adults than 
those aged 50–64 years in both industrialized countries and de-
veloping countries. The hCFR was higher in developing coun-
tries as compared to industrialized countries, with overlapping 
95% CIs, for both age groups. The overall number of in-hospital 
deaths in older adults was 14 100 (UR, 4800–50 500) in 2015. 
Data were insufficient to provide global and regional death 
estimates stratified by gender or RSV subtype. One study from 
Guatemala reported deaths in 61.5% of patients (8 of 13) aged 
≥50  years with very severe RSV-ARI (ie, requiring intensive 
care unit admission or mechanical ventilation) [17].
DISCUSSION
This is the first systematic review to evaluate and summarize 
the available literature and unpublished data and estimate the 
burden of RSV-ARI in older adults. Our review summarized 
data from about 18  000 cases of RSV-ARI in older adults re-
ported in 36 articles and 8 unpublished studies. Our study 
showed a substantial disease burden of RSV-ARI in older 
adults. We estimated that, in 2015, there were about 1.5 mil-
lion episodes of RSV-ARI (95% CI, 0.3 million–6.9 million) 
in older adults in industrialized countries and that, of these 
episodes, 214  000 (95% CI, 100  000–459  000; approximately 
14.5%) involved hospital admission. The global number of hos-
pital admissions for RSV-ARI in older adults was estimated 
at 336 000 (UR, 186 000–614 000). A plausibility check using 
an independent approach with nonoverlapping data from 
19 different studies was in good agreement with our hospital 
Table 1. Estimates of the Incidence, Hospital Admission Rate, In-Hospital Case-Fatality Ratio (hCFR), and Number of Episodes and In-Hospital Deaths 
Among Older Adults Aged ≥65 Years With Respiratory Syncytial Virus (RSV)–Associated Acute Respiratory Infection (ARI), 2015
Variable Developing Countries Industrialized Countries Globala
Incidence
 Studies, no. 1 5 6
 Incidence, cases/1000 persons per y … 6.7 (1.4–31.5) …
 Cases, no., ×1000 … 1479 (315–6939) …
Hospital admission rate
 Studies, no. 6 6 12
 Hospitalization rate, cases/1000 persons per y 0.3 (.1–.7) 1.0 (.5–2.1) …
 Cases, no., ×1000 109 (45–266) 214 (100–459) 336 (186–614)
RSV positivity among hospitalized ARI cases
 Studies, no. 8 3 11
 Proportion, % 3.0 (1.9–4.9) 4.4 (3.0–6.5) …
 Cases, no., ×1000 113 (69–186) 136 (83–221) 252 (178–360)
hCFR and no. of deaths 
 Studies, no. 5 3 8
 hCFR, % 9.1 (2.6–31.8) 1.6 (.7–3.8) …
 Deaths, no., ×1000 10.1 (2.1–45.5) 3.3 (1.0–10.8) 14.1 (4.8–50.5)
Measures of dispersion are 95% confidence intervals. 
aAlthough the overall numbers of cases and deaths were obtained by summing the region-specific numbers for each of the 10 000 samples in the Monte Carlo simulation, the point estimates 
and uncertainty interval limits for the overall cases are not equal to the sum of the region-specific results.
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admission estimates and supports their validity. We further 
estimated that there were about 14 000 in-hospital deaths (UR, 
5000–50 000) related to RSV-ARI. Because the estimates only 
include individuals who were admitted to the hospital, it is most 
likely a gross underestimate, owing to the limited access to care 
and poor care-seeking behavior in developing countries.
There is some inconsistency between our estimates and esti-
mates from other studies. A  modeling study showed that the 
annual estimate of RSV-associated respiratory and circulatory 
deaths was around 11 000 in the United States, which is similar 
to the number reported by Falsey et al (about 14 000) [2, 46]. 
GBD 2015 estimated that the overall number of deaths due to 
RSV could be as high as 54 820 in older adults globally (with 
76  477 deaths for influenza and 588  961 for pneumococcal 
pneumonia) [1]. This might indicate that a high proportion 
of RSV-associated mortality could happen outside hospitals 
[2]. Moreover, we only included laboratory-confirmed RSV-
associated cases, which could miss a number of cases with late 
presentation or lower viral loads [47].
Estimates vary considerably among regions and study sites. 
Comparisons among studies should be interpreted with cau-
tion because several factors may affect the estimates: method-
ological differences across studies (ie, differences in enrollment 
criteria, case definitions for ARI, case ascertainment method, 
and sample sizes of included studies), annual variations in RSV 
activity, clinical specimens evaluated, sensitivity and speci-
ficity of RSV diagnostic tests, variation in RSV epidemiology 
between study populations, and healthcare-seeking behavior of 
the underlying population. Although we did not include fever 
as part of the case definition, a few studies used a definition of 
severe acute respiratory infection (SARI) that required a history 
of fever or measured fever of ≥38°C, which could have missed 
some RSV cases [48]. Therefore, the true uncertainties around 
these estimates are larger than those expressed in the standard 
95% CIs that we report. This heterogeneity might also result in 
differences when comparing our estimates to those from other 
studies [2, 46]. The hospitalization rate was higher for those 
aged ≥65 years than those aged 50–64 years (with overlapping 
95% CIs) in both industrialized and developing countries, 
indicating that age might be an important risk factor for RSV-
ARI–related hospital admissions among those ≥50  years. The 
hospitalization rate was higher in industrialized countries than 
in developing countries, with overlapping 95% CIs. This may 
be largely explained by the higher proportion of older adults 
and lower thresholds for hospital admission in industrialized 
countries and by poor care-seeking behavior in developing 
countries. However, the hCFR in industrialized countries was 
lower than in developing countries (with overlapping 95% CIs). 
The poorer outcome might reflect delayed presentation and less 
optimal case management strategies in developing countries, 
including lack of supportive care (including mechanical venti-
lation), suboptimal treatment of secondary bacterial infections, 
or suboptimal control of underlying conditions such as chronic 
obstructive pulmonary disease or diabetes.
Our estimates of RSV-ARI morbidity and mortality are 
limited by data availability in developing countries, where 
outcomes may be poorer. Of the 24 studies from developing 
countries, most reported the proportion of admissions of RSV-
positive individuals (without a clear population denominator), 
and none provided community-based RSV-ARI incidence 
or mortality rates. Estimates from developing countries were 
missing for some WHO regions (the Eastern Mediterranean 
Region, the South-East Asia Region, and much of the African 
Region). The hospital admission estimates of RSV-ARI from de-
veloping countries came largely from studies where the catch-
ment population had relatively good access to care. We expect 
that many adults with severe or very severe RSV-ARI in devel-
oping countries do not receive prompt hospital care. Therefore, 
our global and regional estimates likely underestimate the true 
burden of RSV-ARI in both community and hospital settings. 
Further estimates of the overall RSV-ARI mortality from pop-
ulation-based studies with demographic surveillance could 
provide additional data to allow more-robust estimates. Better 
surveillance systems, including standard case definitions and 
reporting practices, would substantially reduce the uncertainty 
in the RSV-ARI morbidity and mortality estimates. Currently 
an RSV surveillance pilot is being built on the WHO Global 
Influenza Surveillance and Response System platform, which 
included countries implementing community-based RSV sur-
veillance and hospital-based RSV surveillance [49].
Few data are available stratified by narrower age groups or 
by sex. Therefore, the overall estimate for older adults was gen-
erated directly from the incidence or hospital admission rate 
for the group aged ≥65 years. Although our results showed that 
the hospital admission rate and hCFR increased with age, which 
indicates that age might be a risk factor for RSV-ARI in those 
aged ≥50 years, the number of available studies was limited and 
restricted to 2 age groups (≥65 years and 50–64 years). More 
studies with age- and sex-specific data are required, to provide 
more-robust evidence. Data were insufficient to provide esti-
mates of the regional incidence or hospitalization rate stratified 
by RSV subtype. One community cohort study reported that 
both RSV antigenic groups circulated each year without sig-
nificant differences in the proportion of each subtype among 
both outpatients and inpatients [12]. Moreover, only 1 study 
provided the hospital admission rate and hCFR for older adults 
with very severe RSV-ARI [17].
A low RSV detection rate in older adults may be due to the 
low awareness of RSV infection, challenges in diagnosing RSV 
in clinical practice, difficulty in obtaining appropriate clinical 
specimens for testing, insensitivity of some of the current di-
agnostic tests, and relatively high cost of polymerase chain re-
action analysis. Moreover, older adults usually have atypical or 
delayed clinical presentations with very low viral loads, which 
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further decreases the sensitivity of diagnostic tests, particularly 
those for antigen testing [47]. They may not have detectable 
virus when they visit the clinics or hospitals, owing to a shorter 
duration of shedding, delay in presentation for care, or inappro-
priate specimen collection [11].
Although age might be a risk factor for RSV-ARI in adults 
aged >50  years, the majority of older adults who have been 
studied had underlying medical conditions, such as congestive 
heart failure and chronic obstructive pulmonary disease, which 
are associated with an increased risk of RSV-ARI and poor 
outcome. Moyes et  al [37] reported that the hospital admis-
sion rate among individuals with RSV-ARI was around 1.0–4.8 
cases/1000 persons per year in HIV-infected older adults, while 
the rate was 0.2 cases/1000 persons per year in those without 
HIV infection (which translates to a relative risk between 5 and 
24). Thus, comorbidities should be taken into consideration 
when evaluating the role of age in RSV-ARI hospitalizations. 
Most studies included participants with and those without 
comorbidities and did not report comorbidity-specific disease 
burdens. One study presented the hCFR of RSV-ARI in patients 
with and those without immunocompromised status among 
individuals aged ≥60 years (7.0% vs 6.8%) [24]. Falsey et al [2] 
reported that the hCFR of RSV-ARI in older adults hospital-
ized with acute cardiopulmonary conditions was 7.6%, which 
is higher than the hCFR from our meta-estimate for industri-
alized countries. Further research into the high-risk profiles of 
older adults admitted to hospitals with severe RSV-ARI could 
help guide management strategies, reducing RSV-ARI hospital-
ization and improving outcomes.
According to Falsey et  al, in US residents aged ≥65  years, 
RSV infection accounted for 10.6% of hospitalizations for pneu-
monia, 11.4% for chronic obstructive pulmonary disease, 5.4% 
for congestive heart failure, and 7.2% for asthma [2]. Therefore, 
the estimate from this report on RSV-ARI could underesti-
mate the overall disease burden attributable to RSV infection. 
Moreover, our study was limited to hospitalized patients and 
did not account for the substantial outpatient burden of RSV 
disease.
Causal attribution of RSV infection in older adults is best 
assessed in case-control studies. However, asymptomatic RSV 
infection is uncommon, occurring in only about 10% of asymp-
tomatic participants [50]. Our recent meta-analysis suggests 
that there was strong evidence for the association, indicating 
possible causal attribution for RSV in older adults presenting 
with ARI, compared with those without respiratory symptoms 
or healthy older adults [50]. Among individuals with RSV-ARI, 
ARI is causally attributable to RSV in about 88%.
In conclusion, this study provides a review of the existing 
evidence regarding the RSV-ARI burden in community and 
hospital settings in older adults aged ≥65 years. RSV-ARI is an 
important disease among older adults. More high-quality data 
(including detailed age-stratified data) on RSV-ARI morbidity 
and mortality with larger sample sizes will improve the disease 
burden estimate and help guide targeted interventions, such as 
vaccination.
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